a helper adenovirus of a first serotype under conditions whereby little or no infectious particles of helper virus are present in the final hdAd stock, but wherein said stock is highly enriched in infectious particles comprising said hdAd genome and capsid proteins encoded by said helper adenovirus of said first serotype;

(d) repeating step (c) as many times as desired using a helper adenovirus of a different serotype each time said step (c) is repeated, such that a series of infectious hdAd stocks are generated, with each said stock having said different set of capsid proteins based on said different serotype; and

(e) recovering said infectious hdAd stocks having a capsid of different serotype to obtain said series of genetically identical adenoviral vectors.

Add the following claim:

Claim 15 (New claim)

15. The adenoviral vector gene delivery system of claim 1 wherein, in a series of said packaged helper dependent adenoviruses, at least two helper adenoviruses are from one subgroup of adenoviruses; and the serotypes of said at least two helper adenoviruses do not give rise to cross reactive antibodies when administered to a subject in need of said adenoviral vector gene delivery system.

REMARKS

Consideration of the amendments presented herein and reconsideration of all grounds for rejection is respectfully requested. Claims 1-14 are pending in the application. Claims 5-7 and 10-12 stand withdrawn from consideration as being drawn to non-elected subject matter. Claims 1-4, 8, 9, 13 and 14 stand rejected.

Claim 15 has been added in this response, to specifically claim one aspect of the present invention